CZEN-002
CZEN-002 had been in phase II clinical trials for the treatment of vulvovaginal candidiasis. However, no recent development has been reported.
It was developed by Zengen, Abiogen Pharma and Lee's pharmaceuticals.
General Information
Update Date：2016-06-08
- Drug Name：
- CZEN-002
- Research Code：
- CZEN-002
- Trade Name：
- MOA：
- NF-κB activation inhibitor
- Indication：
- Candidiasis
- Status：
- Phase Ⅱ (Pending)
- Company：
- Abiogen (Originator), Zengen (Originator), Lee's pharmaceuticals (Originator)
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-11-04
|
Molecular Weight | 971.24 | ||||||||||||
| Formula | C42H74N12O10S2 | |||||||||||||
| CAS No. | 457605-12-8 (CZEN-002); | |||||||||||||
| Chemical Name | L-Valinamide, N-acetyl-L-cysteinyl-L-lysyl-L-prolyl-, bimol. (1®1')-disulfide | |||||||||||||
| CZEN-002 （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||